Merckâ€™s Keytruda improves overall survival in phase 3 esophageal cancer trial

Merck has announced that its anti-PD-1 therapy Keytruda (pembrolizumab) significantly improved overall survival (OS) rate in the phase 3 Keynote-181 esophageal cancer trial.

Merck’s Keytruda improves overall survival in phase 3 esophageal cancer trial

AUDIENCES

Caregivers
Friends and Family
General Public
Medical Profession
Patients
Survivors

SUBJECTS

Post Surgical

Disclaimer: This information is for educational purposes only, It is not to diagnose or treat your disease. If you do use the information contained on this web site without the approval of a health professional, you are prescribing for yourself, which is your constitutional right, but the author(s) and webmaster assume no responsibility

© 2024 Esophageal Cancer Education Foundation- by domino